Patent Application: T-cell receptors target mutant RAS for cancer treatment
Summary
The USPTO has published patent application US20260083847A1 concerning T-cell receptors and compositions for treating cancer associated with mutant RAS. The application details methods and compositions involving T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.
What changed
This document is a published patent application (US20260083847A1) from the USPTO, filed on September 13, 2023. It describes T-cell receptors and related compositions designed to target mutant RAS for cancer treatment. The invention focuses on T-cell receptors that bind to specific mutant RAS peptide fragments within particular HLA types, and also includes multispecific antibodies incorporating these T-cell receptors.
As this is a patent application, it does not impose immediate regulatory obligations or compliance deadlines on entities. However, it signals potential future developments in cancer therapeutics and immunotherapy. Companies involved in drug development, particularly in oncology and immunotherapy, should monitor the progress of this and similar patent applications as they may indicate emerging technologies and intellectual property landscapes in the field.
Archived snapshot
Mar 27, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
T-CELL RECEPTORS AND COMPOSITIONS THEREOF FOR TARGETING MUTANT RAS
Application US20260083847A1 Kind: A1 Mar 26, 2026
Inventors
Adham Bear, Beatriz Carreno, Gerald Linette, Robert Vonderheide
Abstract
The present invention provides compositions and methods of treating cancer associated with mutant RAS. In certain aspects, the present invention provides T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types. In certain aspects, the present invention provides multispecific (e.g., bispecific) antibodies comprising T-cell receptors that bind to specific mutant RAS peptide fragments in the context of specific HLA types.
CPC Classifications
A61K 40/32 A61K 35/17 A61K 38/00 A61K 40/11 A61K 40/15 A61K 40/42 A61P 35/00 C07K 14/7051 C12N 5/0636 C12N 5/0646 C12N 15/62 C07K 2317/31 C07K 2317/565 C07K 2319/00
Filing Date
2023-09-13
Application No.
19111631
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.